前列腺原发性间叶肿瘤的18F-FDG PET/CT表现
该研究纳入13例经病理证实的前列腺间叶肿瘤患者,回顾性分析其18F-FDG PET/CT表现。结果显示肿瘤体积大、SUVmax、MTV和TLG水平高,精囊腺、直肠和膀胱为最常见侵犯部位,骨、肺和淋巴结为常见转移部位。作者认为18F-FDG PET/CT可能有助于准确诊断、分期和再分期。
要点
- 13例前列腺间叶肿瘤患者中位年龄38岁,肿瘤平均直径8.8 cm。
- SUVmax范围3.1–17.6(平均9.5),MTV平均109 cm3,TLG平均96 g。
- 精囊腺、直肠和膀胱为最常见侵犯部位,骨、肺和淋巴结为典型转移部位。
核心结论
- 前列腺间叶肿瘤在18F-FDG PET/CT上表现为体积大且SUVmax、MTV和TLG水平高。
- 作者认为18F-FDG PET/CT可能有助于准确诊断、分期和再分期,对后续治疗计划有重要作用。
研究设计与样本
- 纳入13例经病理证实的前列腺间叶肿瘤患者,回顾性分析其18F-FDG PET/CT表现。
主要发现
- 13例患者中位年龄38岁(范围13–74岁),肿瘤平均直径8.8 cm(范围5–16.1 cm)。
- SUVmax范围3.1–17.6(平均9.5),MTV范围4.9–398 cm3(平均109 cm3),TLG范围21.3–1216 g(平均96 g)。
- 精囊腺、直肠和膀胱为最常见侵犯部位,转移通常发生于骨、肺和淋巴结。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary mesenchymal tumors of the prostate are very rare, and there is no systematic report on fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT). The aim of this research was to characterize mesenchymal tumors of the prostate on 18F-FDG PET/CT. RESULTS: We included 13 patients with pathologically confirmed mesenchymal neoplasms of the prostate. The location, size, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total glycolysis of the lesion (TLG), pathologic findings, and available imaging study of the tumors were reviewed. Of the 13 patients (median age, 38 years; ranged from 13 to 74 years), the mean size of the tumors was 8.8 cm in diameter ranged from 5 to 16.1 cm. SUVmax ranged from 3.1 to 17.6 (mean 9.5), MTV ranged from 4.9 to 398 cm3 (mean 109 cm3) and TLG ranged from 21.3 to 1216 g (mean 96 g). The seminal vesicles, rectum, and bladder are the most commonly affected sites of invasion, while metastasis typically occurs in the bones, lungs, and lymph nodes. CONCLUSIONS: Mesenchymal tumors of the prostate revealed large sizes and high SUVmax, MTV and TLG levels on 18F-FDG PET/CT. 18F-FDG PET/CT may be useful for accurate diagnosis, staging, and restaging, which plays an important role in the management of subsequent plans.
引用
- Tao Z, Qiu Y, Chen Z, et al. Primary mesenchymal tumors of the prostate:18F FDG PET/CT findings. EJNMMI Res. 2024. PMID: 39542970. doi:10.1186/s13550-024-01177-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。